Diabetes
Discover unique market-leading data and insights into the Diabetes market. From the latest Diabetes industry reports and analysis to comprehensive market growth forecasts, trends and research.
Browse our full list of Diabetesmarket reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
Product Insights Diabetic Foot Ulcers – Drugs In Development, 2023 Diabetic Foot Ulcers – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Diabetic Foot Ulcers - Drugs In Development, 2023’, provides an overview of the Diabetic Foot Ulcers pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Product Insights Diabetic Nephropathy – Drugs In Development, 2023 Diabetic Nephropathy – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Diabetic Nephropathy - Drugs In Development, 2023’, provides an overview of the Diabetic Nephropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights Diabetic Neuropathy – Drugs In Development, 2023 Diabetic Neuropathy – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Diabetic Neuropathy - Drugs In Development, 2023’, provides an overview of the Diabetic Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights Non-Proliferative Diabetic Retinopathy (NPDR) – Drugs In Development, 2023 Non-Proliferative Diabetic Retinopathy (NPDR) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Non-Proliferative Diabetic Retinopathy (NPDR) - Drugs In Development, 2023’, provides an overview of the Non-Proliferative Diabetic Retinopathy (NPDR) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Proliferative Diabetic Retinopathy (NPDR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Diabetic Retinopathy – Drugs In Development, 2023 Diabetic Retinopathy – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Diabetic Retinopathy - Drugs In Development, 2023’, provides an overview of the Diabetic Retinopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights Diabetic Macular Edema – Drugs In Development, 2023 Diabetic Macular Edema – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Diabetic Macular Edema - Drugs In Development, 2023’, provides an overview of the Diabetic Macular Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Product Insights Proliferative Diabetic Retinopathy (PDR) – Drugs In Development, 2023 Proliferative Diabetic Retinopathy (PDR) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Proliferative Diabetic Retinopathy (PDR) - Drugs In Development, 2023’, provides an overview of the Proliferative Diabetic Retinopathy (PDR) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Diabetic Peripheral Neuropathy – Drugs In Development, 2023 Diabetic Peripheral Neuropathy – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Diabetic Peripheral Neuropathy - Drugs In Development, 2023’, provides an overview of the Diabetic Peripheral Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
Sector Analysis Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
$3,495 | August 2023 Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Report Overview Diabetic Nephropathy (DN) is glomerular sclerosis and fibrosis caused by the metabolic and hemodynamic changes of diabetes mellitus (DM). It manifests as slowly progressive albuminuria with worsening hypertension and renal insufficiency. DN is the most common cause of nephrotic syndrome in adults and is also the most common cause of end-stage renal disease (ESRD) in the US, accounting for up to 80% of cases. Renal failure is particularly common in certain...
-
Thematic Analysis
Thematic Analysis Digital Marketing Trends in Type 2 Diabetes Digital Marketing Trends in Type 2 Diabetes
$1,950 | June 2023 Digital Marketing Trends in Type 2 Diabetes Report Overview Novo Nordisk's Ozempic.com achieved the highest total traffic across type 2 diabetes (T2D) patient brand sites in the US, with over 23 million visitors between April 2022–March 2023, followed by Eli Lilly's Trulicity.com and AstraZeneca's Farxiga.com. The highest proportion of traffic to branded patient T2D websites originated from direct sources, followed by organic. Novo Nordisk’s Rybelsus.com had the highest proportion of direct traffic. The Digital Marketing Trends in the Type 2...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.